# Safety and Efficacy of Fingolimod in MS Patients in China

> **NCT01941004** · PHASE3 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Multiple Sclerosis (Relapsing Remitting)

## Interventions

- **DRUG:** fingolimod
- **DRUG:** Placebo (6mos) + open label fingolimod (6 mos)

## Key facts

- **NCT ID:** NCT01941004
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-06
- **Primary completion:** 2017-05
- **Final completion:** 2017-05
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01941004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01941004, "Safety and Efficacy of Fingolimod in MS Patients in China". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01941004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*